Entinostat for treatment of solid tumors and hematologic malignancies

Bibliography

• Hu E, Dul E, Sung CM, Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003;307(2):720-8
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26(37):5541-52
   PubMed Web of Science ®Google Scholar
• Ryan QC, Headlee D, Acharya M, Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23(17):3912-22
   PubMed Web of Science ®Google Scholar
• Kummar S, Gutierrez M, Gardner ER, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13(18 Pt 1):5411-17
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemjit A, Trepel JB, Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109(7):2781-90
   PubMed Web of Science ®Google Scholar
• Gore L, Rothenberg ML, O'Bryant CL, A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14(14):4517-25
   PubMed Web of Science ®Google Scholar
• Hauschild A, Trefzer U, Garbe C, Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 2008;18(4):274-8
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420-32
   PubMed Web of Science ®Google Scholar
• Fouladi M. Histone deacetylase inhibitors in cancer therapy. Cancer Invest 2006;24(5):521-7
   PubMed Web of Science ®Google Scholar
• Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15(12):3958-69
   PubMed Web of Science ®Google Scholar
• Tan J, Cang S, Ma Y, Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12(10):1247-52
   PubMed Web of Science ®Google Scholar
• Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 2009;45(11):787-95
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
   PubMed Web of Science ®Google Scholar
• Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol 2010;22(5):431-6
   PubMed Web of Science ®Google Scholar
• Saito A, Yamashita T, Mariko Y, A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96(8):4592-7
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ando T, Tsuchiya K, Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999;42(15):3001-3
   PubMed Web of Science ®Google Scholar
• Simonini MV, Camargo LM, Dong E, The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006;103(5):1587-92
   PubMed Web of Science ®Google Scholar
• Acharya MR, Sparreboom A, Sausville EA, Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 2006;57(3):275-81
   PubMed Web of Science ®Google Scholar
• Acharya MR, Karp JE, Sausville EA, Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 2006;24(5):367-75
   PubMed Web of Science ®Google Scholar
• Vire B, de Walque S, Restouin A, Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. PLoS One 2009;4(9):e7085
   Web of Science ®Google Scholar
• Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005;25(13):5429-44
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Yang J, Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 2008;22(12):2159-68
   PubMed Web of Science ®Google Scholar
• Tsapis M, Lieb M, Manzo F, HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 2007;39(7-8):1500-9
   PubMed Web of Science ®Google Scholar
• Lucas DM, Davis ME, Parthun MR, The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004;18(7):1207-14
   PubMed Web of Science ®Google Scholar
• Maggio SC, Rosato RR, Kramer LB, The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 2004;64(7):2590-600
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63(13):3637-45
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Yang J, Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 2008;22(7):1449-52
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Yang J, MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 2008;32(9):1382-92
   PubMed Web of Science ®Google Scholar
• Miller CP, Ban K, Dujka ME, NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110(1):267-77
   PubMed Web of Science ®Google Scholar
• Gao S, Mobley A, Miller C, Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk Res 2008;32(5):771-80
   PubMed Web of Science ®Google Scholar
• Lee CK, Wang S, Huang X, HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett 2010;296(2):233-40
   PubMed Web of Science ®Google Scholar
• Sato T, Suzuki M, Sato Y, Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 2006;28(5):1233-41
   PubMed Web of Science ®Google Scholar
• Bracker TU, Sommer A, Fichtner I, Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol 2009;35(4):909-20
   PubMed Web of Science ®Google Scholar
• Flis S, Gnyszka A, Splawinski J. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun 2009;387(2):336-41
   PubMed Web of Science ®Google Scholar
• Flis S, Gnyszka A, Flis K, Splawinski J. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. Eur J Pharmacol 2010;627(1-3):26-32
   PubMed Web of Science ®Google Scholar
• Zhang Y, Adachi M, Zhao X, Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 2004;110(2):301-8
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Grimes MJ, Picchi MA, Combination therapy with Vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 2011;71(2):454-62
   PubMed Web of Science ®Google Scholar
• Witta SE, Dziadziuszko R, Yoshida K, ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 2009;20(4):689-95
   PubMed Web of Science ®Google Scholar
• Brazelle W, Kreahling JM, Gemmer J, Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS ONE 2010;5(12):e14335
   PubMed Web of Science ®Google Scholar
• Kakihana M, Ohira T, Chan D, Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol 2009;4(12):1455-65
   PubMed Web of Science ®Google Scholar
• Witta SE, Gemmill RM, Hirsch FR, Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66(2):944-50
   PubMed Web of Science ®Google Scholar
• Qian DZ, Wei YF, Wang X, Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 2007;67(11):1182-93
   PubMed Web of Science ®Google Scholar
• Nguyen TL, Abdelbary H, Arguello M, Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 2008;105(39):14981-6
   PubMed Web of Science ®Google Scholar
• Bjorkman M, Iljin K, Halonen P, Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 2008;123(12):2774-81
   PubMed Web of Science ®Google Scholar
• Camphausen K, Burgan W, Cerra M, Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64(1):316-21
   PubMed Web of Science ®Google Scholar
• Camphausen K, Scott T, Sproull M, Tofilon PJ. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 2004;10(18 Pt 1):6066-71
   PubMed Web of Science ®Google Scholar
• Chen CS, Wang YC, Yang HC, Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007;67(11):5318-27
   PubMed Web of Science ®Google Scholar
• Schmudde M, Braun A, Pende D, Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett 2008;272(1):110-21
   PubMed Web of Science ®Google Scholar
• Gediya LK, Belosay A, Khandelwal A, Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem 2008;16(6):3352-60
   PubMed Web of Science ®Google Scholar
• Khandelwal A, Gediya L, Njar V. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer 2008;98(7):1234-43
   PubMed Web of Science ®Google Scholar
• Sun P, Xia S, Lal B, DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells 2009;27(7):1473-86
   PubMed Web of Science ®Google Scholar
• Eyupoglu IY, Hahnen E, Trankle C, Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 2006;5(5):1248-55
   PubMed Web of Science ®Google Scholar
• Sabnis GJ, Goloubeva O, Chumsri S, Functional activation of the Estrogen Receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011;71(5):1893-903
   PubMed Web of Science ®Google Scholar
• Huang X, Gao L, Wang S, HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 2009;69(21):8403-11
   PubMed Web of Science ®Google Scholar
• Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005;24(29):4609-23
   PubMed Web of Science ®Google Scholar
• Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010;9(12):3254-66
   PubMed Web of Science ®Google Scholar
• Lee BI, Park SH, Kim JW, MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res 2001;61(3):931-4
   PubMed Web of Science ®Google Scholar
• Xu J, Zhou JY, Wei WZ, Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 2008;68(16):6718-26
   PubMed Web of Science ®Google Scholar
• Qu W, Kang YD, Zhou MS, Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol Oncol 2010;28(6):648-54
   PubMed Web of Science ®Google Scholar
• Baradari V, Huether A, Hopfner M, Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006;13(4):1237-50
   PubMed Web of Science ®Google Scholar
• Dzieran J, Beck JF, Sonnemann J. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Sci 2008;99(8):1685-92
   PubMed Web of Science ®Google Scholar
• Gahr S, Peter G, Wissniowski TT, The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol Rep 2008;20(5):1249-56
   PubMed Web of Science ®Google Scholar
• Wang XF, Qian DZ, Ren M, Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005;11(9):3535-42
   PubMed Web of Science ®Google Scholar
• Kato Y, Yoshimura K, Shin T, Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 2007;13(15 Pt 1):4538-46
   PubMed Web of Science ®Google Scholar
• Holsken A, Eyupoglu IY, Lueders M, Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol 2006;112(2):205-15
   PubMed Web of Science ®Google Scholar
• Liu S, Cheng H, Kwan W, Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther 2008;7(6):1751-61
   PubMed Web of Science ®Google Scholar
• Baradari V, Hopfner M, Huether A, Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 2007;13(33):4458-66
   PubMed Web of Science ®Google Scholar
• Altmann A, Eisenhut M, Bauder-Wust U, Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 2010;37(12):2286-97
   PubMed Web of Science ®Google Scholar
• Hacker S, Dittrich A, Mohr A, Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009;28(35):3097-110
   PubMed Web of Science ®Google Scholar
• Furchert SE, Lanvers-Kaminsky C, Juurgens H, Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007;120(8):1787-94
   PubMed Web of Science ®Google Scholar
• Jaboin J, Wild J, Hamidi H, MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62(21):6108-15
   PubMed Web of Science ®Google Scholar
• Aguilera DG, Das CM, Sinnappah-Kang ND, Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 2009;93(3):303-18
   PubMed Web of Science ®Google Scholar
• Dalgard CL, Van Quill KR, O'Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 2008;14(10):3113-23
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Dreyer L, Hartwig M, Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol 2007;133(11):847-58
   PubMed Web of Science ®Google Scholar
• Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int 2008;8:16
   PubMed Web of Science ®Google Scholar
• Mellert HS, Stanek TJ, Sykes SM, Deacetylation of the DNA-binding Domain Regulates p53-mediated Apoptosis. J Biol Chem 2011;286(6):4264-70
   PubMed Web of Science ®Google Scholar
• Glaser KB, Staver MJ, Waring JF, Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2(2):151-63
   PubMed Web of Science ®Google Scholar
• Ungerstedt JS, Sowa Y, Xu WS, Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(3):673-8
   PubMed Web of Science ®Google Scholar
• Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006;66(13):6785-92
   PubMed Web of Science ®Google Scholar
• Di Bernardo G, Alessio N, Dell'Aversana C, Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol 2010;225(2):537-44
   PubMed Web of Science ®Google Scholar
• Niesen MI, Blanck G. Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 2009;32(3):480-2
   PubMed Web of Science ®Google Scholar
• Juergens RAVF, Coleman B, Sebree RS, Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC). J Clin Oncol 2008;26:abstract #19036
   Google Scholar
• Fandy TE, Herman JG, Kerns P, Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114(13):2764-73
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K, Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12(13):3997-4003
   PubMed Web of Science ®Google Scholar